Alfuzosin is a medication classified within men’s health that belongs to the alpha-1 adrenergic antagonist class. It is marketed in a pill form and is commonly available in a 10 mg strength. In Hong Kong, alfuzosin is a prescription-only product regulated by the Department of Health. The drug works by relaxing smooth muscle in the prostate and bladder neck, which helps to alleviate urinary symptoms associated with benign prostatic hyperplasia (BPH).
Alfuzosin selectively blocks alpha-1A adrenergic receptors that are densely located in the prostate, bladder neck, and urethra. By antagonizing these receptors, the medication reduces the tone of smooth muscle in these areas, leading to a widened urethral lumen and improved urinary flow. The onset of symptom relief typically occurs within a few days, with maximal effect observed after several weeks of continuous therapy. Because alfuzosin has limited affinity for vascular alpha-1B receptors, its impact on blood pressure is modest compared with non-selective agents.
Alfuzosin is approved by major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia. In Hong Kong, the Department of Health follows these international approvals and permits alfuzosin for the same indication. The drug is intended for adult males who experience urinary frequency, urgency, nocturia, weak stream, or incomplete bladder emptying due to an enlarged prostate.
Absolute Contraindications
Relative Contraindications
Special Populations
If any of these conditions apply, a healthcare professional should evaluate the risk-benefit profile before initiating therapy.
These effects are generally mild, transient, and may improve with continued use.
Any sudden, severe symptom such as chest pain, severe dizziness, or difficulty breathing warrants immediate medical attention.
Patients should disclose all prescription drugs, over-the-counter medications, supplements, and herbal products before starting alfuzosin.
Routine follow-up visits are recommended to assess symptom improvement and to monitor blood pressure, especially in patients with pre-existing hypertension or those on multiple antihypertensive agents. If urinary symptoms persist or worsen after 4-6 weeks of therapy, the prescriber may consider dose adjustment, alternative medication, or additional diagnostic evaluation.
This article provides educational information about alfuzosin and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Alfuzosin may be combined with other alpha-blockers or 5-alpha-reductase inhibitors only under direct medical supervision, as additive blood-pressure effects or drug interactions can occur.
Both drugs are selective alpha-1A antagonists, but alfuzosin has a longer half-life and is typically taken once daily without a specific dosing time, whereas tamsulosin is often taken 30 minutes after the same meal each day.
Rise slowly from sitting or lying positions, stay hydrated, and avoid driving until you know how the medication affects you. If dizziness is severe or persistent, contact your healthcare provider.
Yes, provided you carry the medication in its original labeled container, keep it in your carry-on luggage, and have a copy of the prescription or a doctor’s note if required by customs.
Alfuzosin does not typically alter standard laboratory values. However, if you are undergoing hormone or prostate-specific antigen (PSA) testing, inform the laboratory of your medication.
Mild to moderate hepatic impairment usually does not require dose adjustment, but a physician should evaluate liver function before initiating therapy.
Rarely, patients may experience blurred vision or changes in visual acuity due to low blood pressure; any visual disturbances should be reported promptly.
St. John’s wort is a known CYP3A4 inducer, which could reduce alfuzosin effectiveness. Discuss any herbal products with your prescriber.
Many men experience symptom relief within a few days, but optimal benefit often occurs after 2-4 weeks of consistent daily dosing.
Avoid taking the tablet with a high-fat meal, as it can decrease absorption. Otherwise, there are no specific food restrictions.
